PPAR¿ Agonists: As Novel Therapeutic Target in Alzheimer¿s Disease - Thakkar, Jalaram
23,99 €
inkl. MwSt.

Versandfertig in 6-10 Tagen
payback
12 °P sammeln
  • Broschiertes Buch

Alzheimer's disease is the most common form of neurodegenerative disorder with dementia. The Alzhemer's disease brain pathology is characterized by deposits of amyloid-beta (Abeta) peptides and neurofibrillary tangles but also (among other aspects) by signs of a chronic inflammatory process.Epidemiological studies have shown that long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk of developing AD and delays its onset. Classical targets of NSAIDs include cycloxygenase, nuclear factor B, and peroxisome proliferator-activated receptors.

Andere Kunden interessierten sich auch für
Produktbeschreibung
Alzheimer's disease is the most common form of neurodegenerative disorder with dementia. The Alzhemer's disease brain pathology is characterized by deposits of amyloid-beta (Abeta) peptides and neurofibrillary tangles but also (among other aspects) by signs of a chronic inflammatory process.Epidemiological studies have shown that long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk of developing AD and delays its onset. Classical targets of NSAIDs include cycloxygenase, nuclear factor B, and peroxisome proliferator-activated receptors.
Autorenporträt
Jalaram Thakkar, Head, Department of Pharmacology, SSR College of Pharmacy, Silvassa, UT of Dadra and Nagar Haveli, obtained his masters degree in Pharmacology with Distinction from Ganpat University and His Ph.D. in pharmacy from HNGU, Patan. He has contributed number of research papers in National and International Journals.